Myriad Genetics Inc. navigates challenges in the biotechnology sector, but remains committed to innovation and patient care, positioning itself for future growth and leadership in genetic medicine.

Myriad Genetics’ stock price dropped over 20% after its Q1 2025 earnings call, despite beating earnings estimates, due to concerns over its future outlook and market challenges in the competitive biotechnology sector.

Myriad Genetics, Inc. is preparing to release its Q1 2025 financial results on May 6, 2025, amidst market fluctuations and valuation challenges in the biotechnology sector.